Comparison of Clinical Targeted Next Generation Sequencing (NGS) in FFPE with Whole Genome Sequencing (WGS) of Snap Frozen Pediatric Brain Tumors
Email Principal Investigator
About this
Project
DNA sequencing is a process by which scientists identify the base chemicals that make up DNA. The order of these base chemicals act like a computer’s code and serve as instructions for how cells should function. Sequencing the DNA found in tumor samples is important for better understanding cancers and creating treatments. Whole Genome Sequencing (WGS) does this for the entire set of genes and each base present in a tumor cell. Next Generation Targeted Sequencing (NGS) processes target areas in the genome that are known to be actionable and drive tumor mechanisms. Researchers will compare WGS sequencing data and targeted sequencing data to validate the targeting sequencing and potentially develop more precise diagnostics for pediatric brain cancers.
Ask The
Scientists
What are the goals of this project?
The goal of this project is to compare and contrast the genetic results of targeted NGS with WGS for patients who have already had both methods of testing.
What is the impact of this project?
Through comparison of WGS data from CBTN and NGS data, researchers will gain insight into how to diagnose and treat pediatric brain tumors.
Why is the CBTN request important to this project?
Researchers have completed targets NGS on many patients also represented in the Pediatric Brain Tumor Atlas. Access to the PBTA is therefore crucial for the completion of this project.
Specimen Data
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.
Explore the data in these informatics portals
Meet The
Team
- Christina Lockwood
- Shannon Stasi
- Karen Tsuchiya
- Kristine Karvonen
Scientific Committee
Bonnie L. Cole, MD
Dr. Bonnie Cole is a pediatric pathologist with expertise in laboratory medicine at Seattle Children's Hospital.
Seattle Children's Hospital
Scientific Committee
Executive Board
Principal Investigator
Sarah Leary, MD
Sarah Leary, MD, MS, is the Medical Director of the Pediatric Brain Tumor Program and the Medical Director of Clinical Research in the Cancer and Blood Disorders Center at Seattle Children’s Hospital. She is an Associate Professor of Pediatrics at the University of Washington School of Medicine and
Seattle Children's Hospital
Site Coordinator
Jeffrey Stevens, BS
I have a background working as the Lead Lab Technician in a cancer lab for over 10 years, and transitioned to working with the CBTN in April of 2014. As the Lead Clinical Research Coordinator at Seattle Children’s for our biology, banking, and precision medicine studies, I manage one of the largest
Seattle Children's Hospital
Christina M. Lockwood, PhD, DABCC, DABMGG
Dr. Lockwood's interests include the development and application of molecular methods for the detection of genomic alterations in genetic disease, hematologic malignancies, and solid tumors. Dr. Lockwood has also been active in the design and implementation of educational resources related to traini
University of Washington
Shannon Stasi, MS
Seattle Children's Hospital
Karen Tsuchiya, MD
Dr. Tsuchiya's main interest is implementing new technology in the clinical laboratory for the diagnosis of pediatric disorders.
Seattle Children's Hospital
Kristine A. Karvonen, MD
Seattle Children's Hospital
Institutions
Primary
Seattle Children's Hospital
Joined onSeattle Children’s Hospital is home to the largest pediatric brain tumor program in the Northwestern United States. With an international reputation for comprehensive care of pediatric brain tumors, Seattle Children’s Brain Tumor Program treats central nervous system (CNS) tumors in children, adoles
University of Washington
related
